Inflammatory mechanisms of adverse reactions to drug-eluting stents

Current Vascular Pharmacology

Volumn 11, Issue 4, 2013, Pages 392-398

  Montone, Rocco A ^a   Sabato, Vito ^a   Sgueglia, Gregory A ^a,b   Niccoli, Giampaolo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

Author keywords

Allergy; Drug eluting stent; Eosinophils; In stent restenosis; Inflammation; Stent thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 12; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; EOSINOPHIL PROTEIN X; EVEROLIMUS; GELATINASE A; GELATINASE B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR BASIC PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MEPOLIZUMAB; PACLITAXEL; PIMECROLIMUS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UMIROLIMUS; UNINDEXED DRUG; ZOTAROLIMUS;

ALLERGIC REACTION; ARTICLE; BARE METAL STENT; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG ELUTING STENT; DRUG MEGADOSE; EOSINOPHIL; FOLLOW UP; HUMAN; HYPERSENSITIVITY; IN STENT RESTENOSIS; INFLAMMATION; LOW DRUG DOSE; NEOINTIMA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; STENT THROMBOSIS; THROMBOSIS;

ANIMALS; C-REACTIVE PROTEIN; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EOSINOPHILS; HUMANS; INFLAMMATION; THROMBOSIS;

EID: 84882787691     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311040003     Document Type: Article

References (74)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007;370:937-48.
2. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
4. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
5. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
6. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
7. Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late catch-up phenomenon from ASPECT Study. J Am Coll Cardiol 2006;48:2432-9.
8. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
9. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
10. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9.
11. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
12. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006 Mar;59(3):232-9.
13. Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009;120:1987-95.
14. Montone RA, Ferrante G, Bacà M, Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol. 2010;6:167-79.
15. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010 Nov 23;56(22):1783-93.
16. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
17. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
18. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-8.
19. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
20. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
21. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis-biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
22. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-11.
23. Stahli BE, Camici GG, Steffel J, et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 2006;99:149-55.
24. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol;56:S43-78.
25. de La Torre Hernandez JM, Alfonso F, Gimeno F, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv. 2010;3(9):911-9.
26. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-8.
27. Welt FG, Tso C, Edelman ER, et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc Med 2003;8:1-7.
28. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-76.
29. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;102:1697-702.
30. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-33.
31. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drugeluting stents. J Am Coll Cardiol 2011;57(11):1314-22.
32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
33. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51.
34. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
35. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-2.
36. Inoue T, Kato T, Uchida T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005;46:239-45.
37. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
38. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
39. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
40. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of Creactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
41. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
42. Park DW, Lee CW, Yun SC, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007;93:1087-92.
43. Niccoli G, Sgueglia GA, Crea F. The emerging role of allergic inflammation in adverse reactions after coronary stent implantation. Atherosclerosis. 2011;217:70-1.
44. Niccoli G, Schiavino D, Belloni F, et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. Eur Heart J 2009;30:1340-7.
45. Gaspardone A, Versaci F, Tomai F, et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006;97:1311-6.
46. Dibra A, Ndrepepa G, Mehilli J, et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 2005;95:1238-40.
47. Kang WC, Ahn TH, Moon CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 2009;95:970-5.
48. Niccoli G, Conte M, Cosentino N, et al. Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. J Invasive Cardiol;23:16-20.
49. Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv;3:90-7.
50. Katsaros KM, Speidl WS, Kastl SP, et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008;6:508-13.
51. Speidl WS, Katsaros KM, Kastl SP, et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis; 208:285-9.
52. Choi DH, Park KW, Yang HM, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol.
53. Delhaye C, Maluenda G, Wakabayashi K, et al. Long-term prognostic value of preprocedural C-reactive protein after drugeluting stent implantation. Am J Cardiol;105:826-32.
54. Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003;12:40-8.
55. Rittersma SZ, Meuwissen M, van der Loos CM, et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 2006;184:157-62.
56. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10.
57. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in human: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1):193-202.
58. Rittersma SZ, Meuwissen M, van der Loos CM, et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 2006;184:157-62.
59. Otsuka Y, Nakamura M, Kokubu N, Tonooka A, Inoue K, Higami T. Diffuse in-stent restenosis of CYPHER(®) stent due to hypersensitivity reaction confirmed by pathohistological findings. Heart Vessels. 2011 Apr 28. [Epub ahead of print].
60. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009 Apr;2(4):291-9.
61. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
62. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002;13:183-8.
63. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445-54.
64. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.
65. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med 1990;172:1271-4.
66. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993;91:1721-30.
67. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006;107:558-65.
68. Niccoli G, Sgueglia GA, Conte M, et al. Eosinophil cationic protein and clinical outcome after bare metal stent implantation. Atherosclerosis;215:166-9.
69. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-8.
70. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European Evaluation of Paclitaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
71. Waksman R. Promise and challenges of bioabsorbable stents. Catheter Cardiovasc Interv 2007;70:407-14.
72. Hezi-Yamit A, Sullivan C, Wong J, et al. Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A. 2009;90(1):133-41.
73. Steffel J, Eberli FR, Lüscher TF, Tanner FC. Drug-eluting stents - what should be improved? Ann Med. 2008;40(4):242-52.
74. Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol;125:803-13.